ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2496

Telerheumatology: A Technology Not Appropriate for All

Zsolt Kulcsar1,2, Daniel Albert3, Ellyn Ercolano4 and John Mecchella5, 1Rheumatology, Dartmouth Hitchcock Medical Center, Lebanon, NH, 2Rheumatology/Leadership Preventive Medicine Residency, Dartmouth Hitchcock Medical Center, lebanon, NH, 3Medicine/Rheumatology, Dartmouth-Hitchcock Med Ctr, Lebanon, NH, 4Telehealth, Dartmouth Hitchcock Center For Telehealth, Lebanon, NH, 5Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: arthritis management, Patient Satisfaction, quality improvement and technology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Quality Measures and Quality of Care Poster Session

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Title: Telerheumatology: A Technology Not
Appropriate For All

Background/Purpose: Access to Rheumatology care in New Hampshire (NH) and
Vermont (VT) is limited, as a large proportion of the population lives in rural
areas (60%) with limited resources. Telerheumatology services developed at Dartmouth-Hitchcock Medical Center (DHMC)
brings
care to these rural regions and improves access. Our previous
work identified two issues with telerheumatology: 1) the
quality of the patient presenter and 2) the appropriateness of the patient for
a telerheumatology visit.  We want to systematically assess the patient
and provider experience to improve the quality of care delivered via telerheumatology. 

Methods: As part of a quality improvement initiative we performed an IRB-exempt
retrospective review of the charts for patients seen in the telerheumatology
clinic at DHMC from October 2011 to December 2014. We also interviewed the
participants: including providers, presenters and patients regarding their
experience of care. We assessed both patient and provider satisfaction with the
experience. We developed a web based educational series on rheumatic disease,
including MSK examination, for the presenter. We used descriptive statistics to
summarize our findings.

Results:
Between October 2011 and December 2014, 176 patients were seen via telerheumatology between two clinical sites over the course
of 244 patient visits.
The
top diagnosis for patients seen was inflammatory arthritis (n=156, 63.9%).
66.4% of the patients were on high risk medications including: steroids,
biologics (infusion and injectable), and DMARDs. Providers filled out surveys
on 9 visits for 70 patient encounters and found that 19% of patients  (13) were inappropriate for the visit type for
two main reasons: diagnosis unclear or diagnosis too complex. Telerheumatology afforded patients shorter travel distances
and travel related money savings. 94% of patients were satisfied with the
remote site staff and treating providers, and 73% of them would like to be seen
via telerheumatology again. We previously provided
presenter education which had no impact on the provider perceived quality of
the visit.

Conclusion: The use of telerheumatology has successfully
increased access to rheumatology care for patients in rural regions of NH and
VT allowing for shorter travel and cost savings. 19% of the patient visits
reviewed were inappropriate for the visit modality.  This evaluation was performed in a setting
without any pre-visit screening, which we believe could be an opportunity to
triage patients to the appropriate visit modality.  We propose a triage mechanism (Table 1) to pair
patients appropriately with the telerheumatology visit
type to ensure an overall high quality experience for patients and providers in
the future.


Disclosure: Z. Kulcsar, None; D. Albert, None; E. Ercolano, None; J. Mecchella, None.

To cite this abstract in AMA style:

Kulcsar Z, Albert D, Ercolano E, Mecchella J. Telerheumatology: A Technology Not Appropriate for All [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/telerheumatology-a-technology-not-appropriate-for-all/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/telerheumatology-a-technology-not-appropriate-for-all/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology